Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ReShape Lifesciences Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
RSLS
Nasdaq
3845
https://www.reshapelifesciences.com/obalon/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ReShape Lifesciences Inc
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
- Mar 28th, 2024 12:31 pm
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
- Mar 4th, 2024 1:31 pm
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
- Feb 22nd, 2024 1:31 pm
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
- Jan 24th, 2024 1:31 pm
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
- Dec 20th, 2023 1:31 pm
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
- Dec 12th, 2023 9:05 pm
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
- Nov 21st, 2023 1:06 pm
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
- Nov 8th, 2023 9:05 pm
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
- Nov 6th, 2023 1:31 pm
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
- Sep 29th, 2023 4:30 pm
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
- Sep 22nd, 2023 12:31 pm
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
- Sep 21st, 2023 12:31 pm
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
- Sep 19th, 2023 12:31 pm
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
- Sep 14th, 2023 12:31 pm
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
- Aug 7th, 2023 8:05 pm
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
- Aug 3rd, 2023 8:05 pm
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
- Jun 29th, 2023 12:31 pm
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
- Jun 28th, 2023 12:31 pm
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
- Jun 26th, 2023 8:05 pm
Life Science Investor Forum: Presentations Now Available for Online Viewing
- Jun 23rd, 2023 12:35 pm
Scroll